{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Hussain A"],"funding":["NIDDK NIH HHS","NHLBI NIH HHS","National Institutes of Health","CSRD VA"],"pagination":["559-571"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7945981"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["77(5)"],"pubmed_abstract":["<h4>Background</h4>Although intensive blood pressure reduction has cardiovascular benefits, the absolute benefit is greater in those at higher cardiovascular disease (CVD) risk.<h4>Objectives</h4>This study examined whether N-terminal pro-B-type natriuretic peptide (NT-proBNP) helps identify subjects at higher risk for CVD events across systolic blood pressure (SBP), diastolic blood pressure (DBP), or pulse pressure (PP) categories.<h4>Methods</h4>Participants from the ARIC (Atherosclerosis Risk In Communities) study visit 4 (1996 to 98) were grouped according to SBP, DBP, or PP categories and further stratified by NT-proBNP categories. Cox regression models were used to estimate hazard ratios for incident CVD (coronary heart disease, ischemic stroke, or heart failure hospitalization) and mortality across combined NT-proBNP and/or BP categories, adjusting for CVD risk factors.<h4>Results</h4>There were 9,309 participants (age: 62.6 ± 5.6 years; 58.3% women) with 2,416 CVD events over a median follow-up of 16.7 years. Within each SBP, DBP, or PP category, a higher category of NT-proBNP (100 to <300 or 300 pg/ml, compared with NT-proBNP <100 pg/ml) was associated with a graded increased risk for CVD events and mortality. Participants with SBP 130 to 139 mm Hg but NT-proBNP ≥300 pg/ml had a hazards ratio of 3.4 for CVD (95% confidence interval: 2.44 to 4.77) compared with a NT-proBNP of <100 pg/ml and SBP of 140 to 149 mm Hg.<h4>Conclusions</h4>Elevated NT-proBNP is independently associated with CVD and mortality across SBP, DBP, and PP categories and helps identify subjects at the highest risk. Participants with stage 1 hypertension but elevated NT-proBNP had greater cardiovascular risk compared with those with stage 2 SBP but lower NT-proBNP. Future studies are needed to evaluate use of biomarker-based strategies for CVD risk assessment to assist with initiation or intensification of BP treatment."],"journal":["Journal of the American College of Cardiology"],"pubmed_title":["Association of NT-ProBNP, Blood Pressure, and Cardiovascular Events: The ARIC Study."],"pmcid":["PMC7945981"],"funding_grant_id":["K24 HL152440","R01 HL150342","R01 HL134320","HHSN268201700003I","HHSN268201700004I","HHSN268201700005I","R01 HL135008","HHSN268201700001I","HHSN268201700002I","HHSN268201700005C","R01 HL143224","I01 CX001112","R01 DK089174","HHSN268201700001C","HHSN268201700002C","HHSN268201700003C","HHSN268201700004C","K24 DK106414","K24 HL152008"],"pubmed_authors":["Hussain A","Virani SS","Hoogeveen RC","de Lemos JA","Ballantyne CM","Bozkurt B","Ndumule C","Sun W","Deswal A","Matsushita K","Nambi V","Shah AM","Selvin E","Aguilar D","McEvoy JW"],"additional_accession":[]},"is_claimable":false,"name":"Association of NT-ProBNP, Blood Pressure, and Cardiovascular Events: The ARIC Study.","description":"<h4>Background</h4>Although intensive blood pressure reduction has cardiovascular benefits, the absolute benefit is greater in those at higher cardiovascular disease (CVD) risk.<h4>Objectives</h4>This study examined whether N-terminal pro-B-type natriuretic peptide (NT-proBNP) helps identify subjects at higher risk for CVD events across systolic blood pressure (SBP), diastolic blood pressure (DBP), or pulse pressure (PP) categories.<h4>Methods</h4>Participants from the ARIC (Atherosclerosis Risk In Communities) study visit 4 (1996 to 98) were grouped according to SBP, DBP, or PP categories and further stratified by NT-proBNP categories. Cox regression models were used to estimate hazard ratios for incident CVD (coronary heart disease, ischemic stroke, or heart failure hospitalization) and mortality across combined NT-proBNP and/or BP categories, adjusting for CVD risk factors.<h4>Results</h4>There were 9,309 participants (age: 62.6 ± 5.6 years; 58.3% women) with 2,416 CVD events over a median follow-up of 16.7 years. Within each SBP, DBP, or PP category, a higher category of NT-proBNP (100 to <300 or 300 pg/ml, compared with NT-proBNP <100 pg/ml) was associated with a graded increased risk for CVD events and mortality. Participants with SBP 130 to 139 mm Hg but NT-proBNP ≥300 pg/ml had a hazards ratio of 3.4 for CVD (95% confidence interval: 2.44 to 4.77) compared with a NT-proBNP of <100 pg/ml and SBP of 140 to 149 mm Hg.<h4>Conclusions</h4>Elevated NT-proBNP is independently associated with CVD and mortality across SBP, DBP, and PP categories and helps identify subjects at the highest risk. Participants with stage 1 hypertension but elevated NT-proBNP had greater cardiovascular risk compared with those with stage 2 SBP but lower NT-proBNP. Future studies are needed to evaluate use of biomarker-based strategies for CVD risk assessment to assist with initiation or intensification of BP treatment.","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Feb","modification":"2025-04-20T03:41:04.451Z","creation":"2025-04-20T03:41:04.451Z"},"accession":"S-EPMC7945981","cross_references":{"pubmed":["33538254"],"doi":["10.1016/j.jacc.2020.11.063"]}}